FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec

被引：8
作者：
Covington, Matthew F. [1 ]
Curiel, Clara N. [2 ]
Lattimore, Lois [3 ]
Avery, Ryan J. [1 ]
Kuo, Phillip H. [4 ,5 ,6 ]
机构：
[1] Banner Univ, Med Ctr Tucson, Univ Arizona, Coll Med,Dept Med Imaging, Tucson, AZ USA
[2] Banner Univ, Med Ctr Tucson, Univ Arizona, Coll Med,Dept Dermatol, Tucson, AZ USA
[3] Banner Univ, Med Ctr Tucson, Univ Arizona, Coll Med,Dept Oncol, Tucson, AZ USA
[4] Univ Arizona, Coll Med, Dept Med Imaging, Tucson, AZ USA
[5] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA
[6] Univ Arizona, Coll Med, Dept Biomed Engn, Tucson, AZ USA
来源：
CLINICAL NUCLEAR MEDICINE | 2017年 / 42卷 / 02期
关键词：
IMLYGIC; immunotherapy; in-transit metastasis; melanoma; PET; T-VEC; talimogene laherparepvec; T-VEC; IMMUNOTHERAPY;
D O I：
10.1097/RLU.0000000000001456
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months following wide local excision and femoral nodal dissection. FDG-PET/CT demonstrated 5 FDG-avid in-transit nodal metastases in the distal left leg, confirmed on biopsy. Talimogene laherparepvec (T-VEC) oncolytic immunotherapy consisting of intralesional injections of modified herpes simplex virus-expressing granulocyte-macrophage colony-stimulating factor was completed over 6 months. Subsequent FDG-PET/CT demonstrated reduced or resolved FDG activity in the treated in-transit metastases and a new FDG-avid left thigh in-transit metastasis. FDG-PET/CT can monitor response to T-VEC and potentially other novel viral immunotherapies. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码：114 / 115
页数：2
相关论文
共 11 条
[1]   Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].
Andtbacka, Robert H. I. ;
Kaufman, Howard L. ;
Collichio, Frances ;
Amatruda, Thomas ;
Senzer, Neil ;
Chesney, Jason ;
Delman, Keith A. ;
Spitler, Lynn E. ;
Puzanov, Igor ;
Agarwala, Sanjiv S. ;
Milhem, Mohammed ;
Cranmer, Lee ;
Curti, Brendan ;
Lewis, Karl ;
Ross, Merrick ;
Guthrie, Troy ;
Linette, Gerald P. ;
Daniels, Gregory A. ;
Harrington, Kevin ;
Middleton, Mark R. ;
Miller, Wilson H., Jr. ;
Zager, Jonathan S. ;
Ye, Yining ;
Yao, Bin ;
Li, Ai ;
Doleman, Susan ;
VanderWalde, Ari ;
Gansert, Jennifer ;
Coffin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98
[2]   Oncolytic Virus Immunotherapy for Melanoma [J].
Dharmadhikari, Neal ;
Mehnert, Janice M. ;
Kaufman, Howard L. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (03)
[3]   Sentinel Node Mapping in Melanoma of the Back SPECT/CT Helps Discriminate "True" and "False" in-Transit Lymph Nodes [J].
Duce, Valerio ;
Manca, Gianpiero ;
Mazzarri, Sara ;
Lorenzetti, Fulvio ;
Colletti, Patrick M. ;
Rubello, Domenico ;
Volterrani, Duccio .
CLINICAL NUCLEAR MEDICINE, 2016, 41 (01) :e66-e67
[4]   Talimogene Laherparepvec: First Global Approval [J].
Greig, Sarah L. .
DRUGS, 2016, 76 (01) :147-154
[5]   Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy [J].
Harrington, Kevin J. ;
Puzanov, Igor ;
Hecht, J. Randolph ;
Hodi, F. Stephen ;
Szabo, Zsolt ;
Murugappan, Swami ;
Kaufman, Howard L. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (12) :1389-1403
[6]   Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma [J].
Hoffner, Brianna ;
Iodice, Gail M. ;
Gasal, Eduard .
ONCOLOGY NURSING FORUM, 2016, 43 (02) :219-226
[7]  
Johnson DB, 2015, IMMUNOTHERAPY-UK, V7, P611, DOI [10.2217/IMT.15.35, 10.2217/imt.15.35]
[8]   Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study [J].
Kaufman, Howard L. ;
Amatruda, Thomas ;
Reid, Tony ;
Gonzalez, Rene ;
Glaspy, John ;
Whitman, Eric ;
Harrington, Kevin ;
Nemunaitis, John ;
Zloza, Andrew ;
Wolf, Michael ;
Senzer, Neil N. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[9]   Talimogene Laherparepvec for the Treatment of Advanced Melanoma [J].
Ott, Patrick A. ;
Hodi, F. Stephen .
CLINICAL CANCER RESEARCH, 2016, 22 (13) :3127-3131
[10]   First oncolytic virus approved for melanoma immunotherapy [J].
Pol, Jonathan ;
Kroemer, Guido ;
Galluzzi, Lorenzo .
ONCOIMMUNOLOGY, 2016, 5 (01)
12